IRIS Institutional Research Information System - OPENBS Open Archive UniBS

FIORENTINI, Chiara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.049
EU - Europa 2.148
AS - Asia 946
SA - Sud America 8
Continente sconosciuto - Info sul continente non disponibili 6
AF - Africa 4
OC - Oceania 4
Totale 7.165
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.031
CN - Cina 597
UA - Ucraina 510
IT - Italia 428
PL - Polonia 378
DE - Germania 232
FI - Finlandia 175
FR - Francia 134
HK - Hong Kong 132
IE - Irlanda 97
GB - Regno Unito 95
SG - Singapore 87
IN - India 71
BE - Belgio 30
SE - Svezia 24
VN - Vietnam 20
CZ - Repubblica Ceca 18
CA - Canada 15
IR - Iran 15
TR - Turchia 11
NL - Olanda 9
EU - Europa 6
AU - Australia 4
CL - Cile 3
ES - Italia 3
KG - Kirghizistan 3
BG - Bulgaria 2
BR - Brasile 2
EG - Egitto 2
JP - Giappone 2
LV - Lettonia 2
MX - Messico 2
PE - Perù 2
PT - Portogallo 2
RO - Romania 2
RU - Federazione Russa 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
AR - Argentina 1
AT - Austria 1
CH - Svizzera 1
GE - Georgia 1
HU - Ungheria 1
IL - Israele 1
JO - Giordania 1
KR - Corea 1
MA - Marocco 1
PA - Panama 1
PK - Pakistan 1
SI - Slovenia 1
TH - Thailandia 1
ZA - Sudafrica 1
Totale 7.165
Salva come PNG Salva come JPEG
Città #
Fairfield 556
Woodbridge 487
Jacksonville 390
Warsaw 378
Houston 323
Chandler 274
Ashburn 273
Cambridge 212
Brescia 205
Seattle 202
Ann Arbor 196
Wilmington 184
Princeton 182
Nanjing 134
Hong Kong 130
New York 122
Helsinki 103
Dublin 97
Beijing 89
Dearborn 70
Singapore 52
Nanchang 48
Shanghai 42
Hebei 39
Shenyang 38
Des Moines 34
San Diego 32
Tianjin 32
Milan 31
Jinan 30
Changsha 27
Brussels 26
Pune 26
Lancaster 23
Jiaxing 22
San Mateo 22
Dong Ket 20
San Donà Di Piave 17
Kunming 16
Hangzhou 15
Brno 14
London 14
San Francisco 14
Ardabil 13
Leawood 13
Toronto 12
Verona 11
Ningbo 10
Kocaeli 9
Augusta 8
Fuzhou 8
Monmouth Junction 8
Boardman 7
Guangzhou 7
Isola Vicentina 7
Lappeenranta 7
Norwalk 7
Taizhou 6
Zhengzhou 6
Munich 5
Teramo 5
Acton 4
Brooklyn 4
Changchun 4
Haikou 4
Kilburn 4
Leipzig 4
Phoenix 4
Redmond 4
Salerno 4
West Jordan 4
Auburn Hills 3
Bishkek 3
Bolzano 3
Chicago 3
Hefei 3
Macerata 3
Mons 3
Olomouc 3
Turin 3
Vicenza 3
Amsterdam 2
Berlin 2
Cairo 2
Canberra 2
Central 2
Genova 2
Groningen 2
Gunzenhausen 2
Hanover 2
Lanzhou 2
Lima 2
Lisbon 2
Lodi 2
Los Angeles 2
Madrid 2
Mexico City 2
Mondovì 2
Mumbai 2
Orange 2
Totale 5.498
Salva come PNG Salva come JPEG
Nome #
MURC/cavin-4 is co-expressed with Caveolin-3 in rhabdomyosarcoma tumors and its silencing prevents myogenic differentiation in the human embryonal RD cell line 275
GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity 231
Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study. 181
Social networks and health status in the elderly: the ‘ANZIANI IN-RETE’ population-based study 160
The "in situ" proximity ligation assay to probe protein-protein interactions in intact tissues 157
Immunotherapy failure in adrenocortical cancer: where next? 157
Role of Dopamine D2/D3 Receptors in Development, Plasticity, and Neuroprotection in Human iPSC-Derived Midbrain Dopaminergic Neurons 154
IN VITRO ANTITUMOR ACTIVITY OF PROGESTERONE IN HUMAN ADRENOCORTICAL CARCINOMA 142
MURC/cavin-4 is co-expressed with Caveolin-3 in rhabdomyosarcoma tumors and its silencing prevents myogenic differentiation in the human embryonal RD cell line 141
The D3 dopamine receptor: From structural interactions to function. 133
Palbociclib inhibits proliferation of human adrenocortical tumor cells 131
Shp-2 knockdown prevents l-dopa-induced dyskinesia in a rat model of Parkinson's disease 124
Persistent activation of the D1R/Shp-2/Erk1/2 pathway in L-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease 123
Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma. 116
Kainate Receptor RNA Editing is Markedly Altered by Acute Spinal Cord Injury. 116
Dopamine D3 and acetylcholine nicotinic receptor heteromerization in midbrain dopamine neurons: Relevance for neuroplasticity 115
Bifunctional compounds targeting both D2 and non-α7 nACh receptors: design, synthesis and pharmacological characterization. 113
The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease 113
The novel hybrid agonist HyNDA-1 targets the D3R-nAChR heteromeric complex in dopaminergic neurons 113
Receptor Heteromers in Parkinson's Disease and L-DOPA-Induced Dyskinesia 107
The tyrosine phosphatase Shp-2 interacts with the dopamine D(1) receptor and triggers D(1) -mediated Erk signaling in striatal neurons. 106
Exploring pre-degenerative alterations in humans using induced pluripotent stem cell-derived dopaminergic neurons 106
Nicotine prevents alpha-synuclein accumulation in mouse and human iPSC-derived dopaminergic neurons through activation of the dopamine D3- acetylcholine nicotinic receptor heteromer 105
Chronic glutamate treatment selectively modulates AMPA RNA editing and ADAR expression and activity in primary cortical neurons 104
The neurobiology of dopamine receptors: evolution from the dual concept to heterodimer complexes 103
Ormoni Anteroipofisari 102
The NMDA/D1 receptor complex as a new target in drug development 97
Role of receptor heterodimers in the development of L-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease. 96
Dimerization of dopamine D1 and D3 receptors in the regulation of striatal function 96
Nerve growth factor suppresses the tumoral phenotype of human prolactinomas 89
CaMKII-dependent phosphorylation regulates SAP97/NR2A interaction 88
Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization 88
Nerve growth factor regulates dopamine D2 receptor expression in prolactinoma cell lines via p75NGFR-mediated activation of nuclear factor-kB. 86
Group-II metabotropic glutamate receptors negatively modulate NMDA transmission at striatal cholinergic terminals: Role of P/Q-type high voltage activated Ca++ channels and endogenous dopamine 85
Nerve growth factor and retinoic acid interactions in the control of small cell lung cancer proliferation. 80
D1 receptor properties are modulated by its oligomerization with NMDA receptors 76
Dopamine D3 receptor heteromerization: Implications for neuroplasticity and neuroprotection 75
Modulation by chronic stress and ketamine of ionotropic AMPA/NMDA and metabotropic glutamate receptors in the rat hippocampus 74
Molecular and pharmacological detection of dopaminergic receptors in the human male urinary tract 73
D1 and D3 dopamine receptors form heterooligomers and cointernalization after paired activation of both receptors 73
Dopamine D3 receptors are critically involved in the neurotrophic effects of cocaine and nicotine on the mouse mesencephalic dopaminergic neurons 73
Generation of two human induced pluripotent stem cell lines, UNIBSi012-A and UNIBSi013-A, from two patients with treatment-resistant depression 72
Role of dopamine D3R/nAChR heterodimeric complex in the regulation of dopaminergic neurons function. 71
A direct interaction between dopamine D1 receptor and phosphatase Shp-2 triggers Erk activation in striatal neurons 69
The Shp-2 tyrosine phosphatase interacts with the dopamine D1 receptor and triggers D1-mediated Erk signalling in striatal neurons. 69
Phenotype changes of prolactinomas 68
Dopamine D1R activation triggers Erk1/2 activation in striatal neurons through the interaction with the protein tyrosine phosphatase Shp-2. 67
Neurotrophic effects of cocaine on mouse mesencephalic dopaminergic neurons are mediated by dopamine D3 receptors 67
Downregulation of dopamine D1/ glutamate NMDA receptor complexes in L-DOPA-induced dyskinesia in the rat 66
Dopamine D1R activation modulates intracellular signalling and triggers Erk1/2 activation in striatal neurons through the interaction with the protein tyrosine phosphatase Shp-2. 66
D1 receptor signalling in basal ganglia function and dysfunctions. 66
Dopamine-induced Erk activation in striatal neurons is mediated by a direct interaction between the D1 receptor and the tyrosine phosphatase Shp-2. 65
Eterodimerizzazione tra recettori dopaminergici D1 e D3: implicazioni funzionali e farmacologiche 65
Down-regulation of the D1R/Shp-2/Erk1/2 pathway ameliorates L-DOPA-induced dyskinesia in the 6-Hydroxy-Dopamine rat model of Parkinson's disease. 64
Dopamine agonists produce neurotrophic effects on mesencephalic dopaminergic neurons via dopamine D3 receptor activation 63
In-vivo silencing of the tyrosine phosphatase Shp-2 ameliorates L-DOPA-induced dyskinesia in a rat model of Parkinson’s disease 62
Establishment and characterization of induced pluripotent stem cell (iPSCs) line UNIBSi014-A from a healthy female donor 57
Impaired dopamine D3 and nicotinic acetylcholine receptor membrane localization in iPSCs-derived dopaminergic neurons from two Parkinson's disease patients carrying the LRRK2 G2019S mutation 57
Role of dopamine D3R and acetylcholine nicotinic receptor interaction in the regulation of dopaminergic neurons function. 56
Molecular mechanisms underlying dopamine D1R-dependent activation of striatal Erk1/2 in L-DOPA induced dyskinesia in a rat model of Parkinson’s disease. 55
Oligomeric assembly of dopamine D1 and glutamate NMDA receptors: molecular mechanisms and functional implications 54
Role of D1 and D3 dopamine receptor heterodimerization in the regulation of the receptor signalling 54
Receptor dimerization and the regulation of neuronal function 53
Functional implications of dopamine D1 and D3 receptor heterodimerization 53
Oligomerization and trafficking of the human dopamine transporter: mutational analysis identifies critical domains important for the functional expression of the transporter. 52
Interactions of Dopamine D1 receptors with D3 receptors and glutamate NMDA receptors 52
Regulation of G-protein coupled receptor trafficking by receptor-receptor interaction 52
Role of dopamine D1 receptor and phosphatase Shp-2 in L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. 52
Knock-down of the tyrosine phosphatase Shp-2 ameliorates L-DOPA-induced dyskinesia in a rat model of parkinson's disease. 52
Growth factors in pituitary tumors 51
Regulation of dopamine D1 receptor trafficking and desensitization by oligomerization with glutamate NMDA receptors 51
Identification and characterization of two Nf-kB binding sites in the human dopamine d2 receptor promotor 51
Ormoni anteroipofisari 51
Regulation of D1 receptor signalling by direct interaction with the protein tyrosine phosphatase SHP-2 49
Oligomerization with NMDA receptor as a novel regulatory mechanism of D1 receptor function 49
Downregulation of dopamine D1/NMDA receptor complexes in the post synaptic densities of dyskinetic rats 47
Extracellular clusterin limits the uptake of α-synuclein fibrils by murine and human astrocytes 47
Loss of Synaptic D1 Dopamine/N-Methyl-D-aspartate Glutamate Receptor Complexes in L-DOPA-Induced Dyskinesia in the Rat. 46
Role of D1 and D3 dopamine receptor heterodimerization in the regulation of receptor trafficking and function 45
Ribociclib Cytotoxicity Alone Or Combined With Progesterone And/Or Mitotane In In Vitro Adrenocortical Carcinoma Cells 44
Identification and characterization of two nuclear factor-kappaB sites in the regulatory region of the dopamine D2 receptor. 42
Oligomerization of dopamine D1 and glutamate NMDA receptors: a new mechanism regulating striatal function” 40
Dendritic remodeling of hippocampal pyramidal neurons, induced by chronic stress and fast-acting antidepressant ketamine, involves miR-9-5p 40
Meccanismo molecolari e cellulari nel Morbo di Parkinson 39
miR-9-5p is involved in the rescue of stress-dependent dendritic shortening of hippocampal pyramidal neurons induced by acute antidepressant treatment with ketamine 38
Induced pluripotent stem cells for defining Parkinsonian patient subtypes: a further step toward precision medicine 37
Farmacologia degli ormoni anteroipofisari 35
Frailty and cognitive impairment in elderly patients: miRNAs as new biomarkers (MATCH-In project) 35
MicroRNAs in frailty associated cognitive impairment MATCH In. 29
Structural Plasticity of Dopaminergic Neurons Requires the Activation of the D3R-nAChR Heteromer and the PI3K-ERK1/2/Akt-Induced Expression of c-Fos and p70S6K Signaling Pathway 29
microRNAs as possible biomarkers of frailty and cognitive impairment: the MATCH-In project 27
The Potential Role of miRNAs in Cognitive Frailty 24
Recent Advances in Dopamine D3 Receptor Heterodimers: Focus on Dopamine D3 and D1 Receptor–Receptor Interaction and Striatal Function 22
microRNAs as new biomarkers in frailty associated with cognitive impairment in elderly patients (MATCH-In project) 22
Central nervous system interaction and crosstalk between nAChRs and other ionotropic and metabotropic neurotransmitter receptors 16
G Protein-Dependent Activation of the PKA-Erk1/2 Pathway by the Striatal Dopamine D1/D3 Receptor Heteromer Involves Beta-Arrestin and the Tyrosine Phosphatase Shp-2 14
Generation of human induced pluripotent stem cell lines derived from three Noonan syndrome patients from a single family carrying the heterozygous PTPN11 c.188 A > G (p.Y63C) mutation 7
In-vitro Approaches to Investigate the Detrimental Effect of Light on Dopaminergic Neurons 5
17-β-estradiol potentiates the neurotrophic and neuroprotective effects mediated by the dopamine D3/acetylcholine nicotinic receptor heteromer in dopaminergic neurons 4
Totale 7.512
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.369
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.369
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.875 283 55 76 193 101 209 208 206 122 211 104 107
2020/20211.317 27 131 46 131 48 127 123 140 167 132 195 50
2021/2022861 61 130 49 24 6 15 91 42 42 103 70 228
2022/2023771 115 9 18 59 70 225 3 78 122 18 23 31
2023/2024758 56 10 69 73 34 173 27 24 137 27 20 108
2024/202513 13 0 0 0 0 0 0 0 0 0 0 0
Totale 7.512